Veru is developing an oral selective androgen receptor modulator (SARM) to mitigate muscle loss in patients undergoing weight loss therapy with GLP-1 drugs. This approach targets the significant issue of muscle degradation associated with current weight loss treatments, aiming to enhance the overall health outcomes for patients.
Funding
$33M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients undergoing weight loss therapy with GLP-1 drugs often experience significant muscle loss, which can negatively impact overall health outcomes. Current weight loss treatments do not adequately address this issue of muscle degradation.
Solution
Veru is developing enobosarm, an oral selective androgen receptor modulator (SARM), to mitigate muscle loss in patients undergoing weight loss therapy with glucagon-like peptide-1 (GLP-1) drugs. Enobosarm is designed to promote high-quality weight loss by reducing fat while preserving muscle mass. The goal is to make the weight loss process healthier and improve patient outcomes. Clinical trials have demonstrated that enobosarm, when added to semaglutide, leads to greater fat loss, preservation of muscle, and fewer gastrointestinal side effects compared to semaglutide alone.
Target Audience
The primary target audience includes patients undergoing weight loss therapy with GLP-1 drugs who are at risk of muscle loss, as well as physicians specializing in obesity and cardiometabolic diseases.
Features
- Oral administration for convenient dosing
- Selective androgen receptor modulation to target muscle tissue
- Designed to preserve muscle mass during weight loss
- Demonstrated positive safety results in Phase 2b QUALITY study
- Potential to reduce gastrointestinal side effects associated with GLP-1 therapies